

Stamp: OIPE MAY 08 2002 BREVETS CITES BY APP TRADEMARK

Serial No.
09/724,341

Applicant
Ashkenazi et al.

Group
~~1614~~ 1644

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
MT	1	WO 02/18620 A2	07.03.02	PCT			<div>RECEIVED</div> <div>MAY 18 2002</div> <div>TECH CENTER 1600/2000</div>	

Date Considered
5/16/03

RECEIVED
MAY 18 2002
TECH CENTER 1600/2909

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)


Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

~~1614~~ 1644

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
MH	1	6,500,428	31.12.02	Bram et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
MH	2	WO 01/58949	16.08.01	PCT			
MH	3	WO 01/87977	22.11.01	PCT			
MH	4	WO 01/87979	22.11.01	PCT			
MH	5	WO 02/094852	28.11.02	PCT			
MH	6	WO 99/00518	07.01.99	PCT			
MH	7	WO 99/28462	10.06.99	PCT			
MH	8	WO 99/33988	08.07.99	PCT			
MH	9	WO 99/35170	15.07.99	PCT			

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

TECH CENTER 1600/2900

MAR 24 2003

RECEIVED

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449


AUG 29 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1805R1

Serial No.
09/724,241

LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)



Applicant
Ashkenazi et al.
Filing Date
28 Nov 2000

Group
1614

FOR FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
HH	1	WO 01/12812	22.02.01	PCT				

Examiner
Maher Haddad

Date Considered
5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
SEP 04 2001
TECH CENTER 1600/2900

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Any Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614/1644

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
mt	1	WO 00/24811	04.05.00	PCT				
mt	2	WO 00/50633	31.08.00	PCT				
mt	3	WO 00/43032	27.07.00	PCT				

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

Examiner

Maher Headdad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 21 2001

Sheet 1 of 8

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614 1644

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
MH	1	307,247 B1	15.03.89	EPO				
	2	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	3	869,180 A1	07.10.98	EPO				
	4	870,827 A2	14.10.98	EPO				
	5	911,633 A1	28.04.99	EPO				
MH	6	WO 00/40716	13.07.00	PCT				
	7	WO 00/67034	09.11.00	PCT				
	8	WO 00/68378	16.11.00	PCT				
	9	WO 97/01633	16.01.97	PCT				
	10	WO 97/25428	17.07.97	PCT				
	11	WO 97/33902	18.09.97	PCT				
	12	WO 98/18921	07.05.98	PCT				
	13	WO 98/27114	25.06.98	PCT				
	14	WO 98/28426	02.07.98	PCT				
	15	WO 98/32856	30.07.98	PCT				
	16	WO 98/35986	20.08.98	PCT				
	17	WO 98/39361	11.09.98	PCT				
	18	WO 98/41629	24.09.98	PCT				
	19	WO 98/46643	22.10.98	PCT				
	20	WO 98/46751	22.10.98	PCT				
	21	WO 98/51793	19.11.98	PCT				
	22	WO 99/02653	21.01.99	PCT				
	23	WO 99/04001	28.01.99	PCT				
	24	WO 99/07738	18.02.99	PCT				
	25	WO 99/09165	25.02.99	PCT				
	26	WO 99/11791	11.03.99	PCT				
	27	WO 99/12964	18.03.99	PCT				
	28	WO 99/12965	18.03.99	PCT				
	29	WO 99/19490	22.04.99	PCT				
	30	WO 99/33980	08.07.99	PCT				
	31	WO 99/50416	07.10.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

MH	32	Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome" <u>Science</u> 259:990-993 (1993)
MH	33	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
MH	34	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40" <u>Nature</u> 357(6373):80-82 (1992)

Examiner

Maher Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614 1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

mh	35	Aruffo et al., "The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome" <u>Cell</u> 72(2):291-300 (1993)
	36	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5381):1305-1308 (1998)
	38	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoaderisin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	38	Baldwin, A., "The NF- κ B and I κ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
	39	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	40	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	41	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	42	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
	43	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
	44	Callard et al., "CD40 ligand and its role in X-linked hyper-IgM syndrome" <u>Immunology Today</u> 14(11):559-564 (1993)
	45	Cathcart et al., "Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen" <u>Laboratory Investigations</u> 54:26-31 (1986)
	46	Chamow and Ashkenazi, "Immunoaderisins: Principles and Applications" <u>Trends in Biotechnology</u> 14:52-60 (1996)
	47	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
	48	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
	49	Courtenay et al., "Immunisation against heterologous type II collagen induces arthritis in mice" <u>Nature</u> 283:666-668 (1980)
	50	Cyster J.G., "B cells on the front line" <u>Nature Immunology</u> 1:9-10 (2000)
	51	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- γ " <u>European Journal of Immunology</u> 17:689-693 (1987)
	52	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
	53	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)
mh	54	Durie et al., "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40" <u>Science</u> 261:1328-1330 (1993)

Examiner

Maher Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAY 21 2000

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

~~1644~~ 1644

LIST OF DISCLOSURES BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

MH	55	Durie et al., "The role of CD40 in the regulation of humoral and cell-mediated immunity" <u>Immunology Today</u> 15(9):406-411 (1994)
	56	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL" <u>Journal of Biological Chemistry</u> 273(23):14363-14367 (1998)
	57	Flanagan and Leder, "The kit ligand: a cell surface molecule altered in steel mutant fibroblasts" <u>Cell</u> 63(1):185-194 (1990)
	58	Foy et al., "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory" <u>Journal of Experimental Medicine</u> 180:157-163 (1994)
	59	Foy et al., "Immune Regulation by CD40 Ligand and its Lingand GP39" <u>Annu. Rev. Immunol.</u> 14:591-617 (1996)
	60	Francisco et al., "In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40" <u>Blood</u> 89(12):4493-4500 (1997)
	61	Futterer et al., "The Lymphotoxin β Receptor Controls Organogenesis and Affinity Maturation in Peripheral Lymphoid Tissues" <u>Immunity</u> 9:59-70 (1998)
	62	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol</u> 7:R750-R753 (1997)
	63	Goodwin et al., "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor" <u>Cell</u> 73(3):447-456 (May 7, 1993)
	64	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
	65	Goodwin et al., "Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor" <u>European Journal of Immunology</u> 23(10):2631-2641 (Oct 1993)
	66	Gras et al., "BCMAP: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes" <u>Int. Immunology</u> 7:1093-1106 (1995)
	67	Gray, D., "Recruitment of virgin B cells into an immune response is restricted to activation outside lymphoid follicles" <u>Immunology</u> 65(1):73-79 (1988)
	68	Grewal et al., "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis" <u>Science</u> 273:1864-1867 (1996)
	69	Gross et al., "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease" <u>Nature</u> 404:945-949 (2000)
	70	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
	71	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth" <u>Journal of Experimental Medicine</u> 188(6):1185-1190 (1998)
	72	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
	73	Han et al., "Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers" <u>J. Immunol.</u> 155(2):556-567 (1995)
MH	74	Harbury et al., "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants" <u>Science</u> 262(5138):1401-1407 (Nov 26, 1993)

Examiner

Maher Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614 1244

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

mt	75	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation" <u>Science</u> 262:905-907 (1993)
	76	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
	77	Holmdahl et al., "Role of T lymphocytes in murine collagen induced arthritis" <u>Agents and Actions</u> 19:295-305 (1986)
	78	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
	79	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)
	80	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
	81	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
	82	Joosten et al., "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF α , anti-IL-1 α/β , and IL-1Ra" <u>Arthritis and Rheumatism</u> 39(5):797-809 (1996)
	83	Kato et al., "Affinity Maturation in Lyn Kinase-Deficient Mice with Defective Germinal Center Formation" <u>J. Immunol.</u> 160:4788-4795 (1998)
	84	Kawabe et al., "The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation" <u>Immunity</u> 1:167-178 (1994)
	85	Khare et al., "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice" <u>Proc. Natl. Acad. Sci. USA</u> 97(7):3370-3375 (2000)
	86	Kim et al., "Detection of Human Leukemia Inhibitory Factor by Monoclonal Antibody Based ELISA" <u>Journal of Immunological Methods</u> 156:9-17 (1992)
	87	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
	88	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
	89	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
	90	Laabi and Strasser, "Lymphocyte Survival - Ignorance Is BLYS" <u>Science</u> 289:883-884 (2000)
	91	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma" <u>EMBO Journal</u> 11:3897-3904 (1992)
	92	Laabi et al., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed" <u>Nucleic Acids Research</u> 22:1147-1154 (1994)
	93	Lane et al., "B cell function in mice transgenic for mCTLA4-Hy1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4 ⁺ T cells" <u>Journal of Experimental Medicine</u> 179(3):819-830 (1994)
mt	94	Ledbetter et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from Variable Regions of mAb G28-5" <u>Critical Reviews in Immunology</u> 17:427-435 (1997)

Examiner

Mahar Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

~~1614~~ 1644

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

mh	95	Lenschow et al., "CD28/B7 System of T Cell Costimulation" <u>Annu. Rev. Immunol.</u> 14:233-258 (1996)
	96	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
	97	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule" <u>Science</u> 257:792-795 (1992)
	98	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
	99	Lotz et al., "The nerve growth factor/tumor necrosis factor receptor family" <u>J. Leukocyte Biol.</u> 60:1-7 (1996)
	100	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
	101	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations" <u>Journal of Experimental Medicine</u> 190:1697-1710 (1999)
	102	MacLennan, I.C., "Germinal Centers" <u>Ann. Rev. Immunol.</u> 12:117-139 (1994)
	103	Madry et al., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily" <u>Int. Immunology</u> 10:1693-1702 (1998)
	104	Maini et al., "Monoclonal anti-TNF α antibody as a probe of pathogenesis and therapy of rheumatoid disease" <u>Immunol. Rev.</u> 144:195-223 (1995)
	105	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	106	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	107	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	108	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	109	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
	110	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
	111	Marsters et al., "Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI" <u>Current Biology</u> 10:785-788 (2000)
	112	Matsumoto et al., "Affinity maturation without germinal centres in lymphotoxin- α -deficient mice" <u>Nature</u> 382:462-466 (1996)
	113	Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator" <u>Immunity</u> 8(1):21-30 (Jan 1998)
mt	114	Mongkolsapaya et al., "Cutting Edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 160(1):3-6 (1998)

Examiner

Maher Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614 1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

mh	115	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
	116	Moore et al., "BLYS: member of the tumor necrosis factor family and B lymphocyte stimulator" <u>Science</u> 285(5425):260-263 (1999)
	117	Morimoto et al., "Abnormalities in CD4+ T-lymphocytes subsets in inflammatory rheumatic diseases" <u>Am. J. Med.</u> 84(5):817-825 (1988)
	118	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, and c-Jun NH ₂ -Terminal Kinase" <u>Journal of Biological Chemistry</u> 274:15978-15981 (1999)
	119	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
	120	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
	121	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(12):6216-6221 (1997)
	122	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
	123	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
	124	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor" <u>FEBS Letters</u> 431(3):351-356 (1998)
	125	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
	126	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling" <u>FEBS Letters</u> 424(1-2):41-45 (1998)
	127	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)
	128	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer" <u>Nature</u> 396(6712):699-703 (1998)
	129	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
	130	Pitzalis et al., "The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homolytic adhesion" <u>European Journal of Immunology</u> 18(9):1397-1404 (1988)
	131	Potocnik et al., "Expression of activation antigens on T cells in rheumatoid arthritis patients" <u>Scand. J. Immunol.</u> 31(2):213-224 (1990)
	132	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
	133	Rennert et al., "A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member APRIL, Inhibits Tumor Cell Growth" <u>Journal of Experimental Medicine</u> 192(11):1677-1683 (2000)
mf	134	Renshaw et al., "Humoral Immune Responses in CD40 Ligand-deficient Mice" <u>Journal of Experimental Medicine</u> 180:1889-1900 (1994)


Examiner

Maker Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

mH	135	Ridley et al., "Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints" <u>Br. J. Rheumatology</u> 29(2):84-88 (1990)
	136	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
	137	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
	138	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" <u>Journal of Experimental Medicine</u> 189:1747-1756 (1999)
	139	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)
	140	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)
	141	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
	142	Seki et al., "Type II collagen-induced murine arthritis: induction of arthritis depends on antigen-presenting cell function as well as susceptibility of host to an anticollagen immune response" <u>J. Immunol.</u> 148:3093-3099 (1992)
	143	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	144	Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens" <u>J. Leukocyte Biol.</u> 65:680-683 (1999)
	145	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
	146	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
	147	Smith et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF" <u>Cell</u> 73(7):1349-1360 (Jul 2, 1993)
	148	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
	149	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" <u>Cell</u> 76:959-962 (1994)
	150	Srivastava et al., "The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains" <u>Proc. Natl. Acad. Sci. USA</u> 94:13069-13074 (1997)
	151	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
	152	Tartaglia et al., "Identification and expression cloning of a leptin receptor, ob-r" <u>Cell</u> 83:1263-1271 (1995)
	153	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
mH	154	Thomas and Quinn, "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" <u>J. Immunol.</u> 156(8):3074-3086 (1996)

Examiner

5/16/03

Date Considered

mH

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1805R1

Serial No.

09/724,341

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Nov 2000

Group

1614 1644

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

MH	155	Thomas et al., "Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells" <u>J. Immunol.</u> 152(5):2613-2623 (1994)
	156	Thompson et al., "BAFF Binds to Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population" <u>Journal of Experimental Medicine</u> 192:129-135 (2000)
	157	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
	158	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
	159	Verma et al., "Rel/NF- κ B/I κ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
	160	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
	161	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
	162	Ware, C.F., "APRIL and BAFF Connect Autoimmunity and Cancer" <u>Journal of Experimental Medicine</u> 192(11):F35-F37 (2000)
	163	Wernick et al., "IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures" <u>Arthritis and Rheumatism</u> 28(7):742-752 (1985)
	164	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
	165	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (1997)
	166	Xia et al., "TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in a B Cell Regulation" <u>Journal of Experimental Medicine</u> 192:137-143 (2000)
	167	Xu et al., "Mice deficient for the CD40 ligand" <u>Immunity</u> 1(5):423-431 (1994)
	168	Yan et al., "Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity" <u>Nature Immunology</u> 1:37-41 (2000)
	169	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)
	170	Yu et al., "APRIL and TALL-1 and receptors BMCA and TACI: system for regulating humoral immunity" <u>Nature Immunology</u> 1(3):252-256 (2000)
MH	171	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)

Examiner

Maker Haddad

Date Considered

5/16/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.